S&P 500   3,154.44 (-0.02%)
DOW   26,272.64 (+0.72%)
FB   236.03 (-1.24%)
GOOGL   1,500.25 (-0.79%)
NVDA   400.94 (-0.29%)
BABA   245.62 (-2.40%)
GE   6.77 (+0.89%)
T   29.91 (+0.47%)
F   6.26 (+2.96%)
BA   177.54 (+1.08%)
S&P 500   3,154.44 (-0.02%)
DOW   26,272.64 (+0.72%)
FB   236.03 (-1.24%)
GOOGL   1,500.25 (-0.79%)
NVDA   400.94 (-0.29%)
BABA   245.62 (-2.40%)
GE   6.77 (+0.89%)
T   29.91 (+0.47%)
F   6.26 (+2.96%)
BA   177.54 (+1.08%)
S&P 500   3,154.44 (-0.02%)
DOW   26,272.64 (+0.72%)
FB   236.03 (-1.24%)
GOOGL   1,500.25 (-0.79%)
NVDA   400.94 (-0.29%)
BABA   245.62 (-2.40%)
GE   6.77 (+0.89%)
T   29.91 (+0.47%)
F   6.26 (+2.96%)
BA   177.54 (+1.08%)
S&P 500   3,154.44 (-0.02%)
DOW   26,272.64 (+0.72%)
FB   236.03 (-1.24%)
GOOGL   1,500.25 (-0.79%)
NVDA   400.94 (-0.29%)
BABA   245.62 (-2.40%)
GE   6.77 (+0.89%)
T   29.91 (+0.47%)
F   6.26 (+2.96%)
BA   177.54 (+1.08%)
Log in

NYSEAMERICAN:BPMXBiopharmx Stock Price, Forecast & News

$2.27
0.00 (0.00 %)
(As of 07/14/2020 10:52 AM ET)
Add
Compare
Today's Range
$2.21
Now: $2.27▼
$2.36
50-Day Range N/A
52-Week Range
$0.25
Now: $2.27▼
$1.18
Volume731,700 shs
Average Volume2.15 million shs
Market Capitalization$41.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.
Read More
Biopharmx logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.22 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:BPMX
Previous SymbolNYSE:BPMX
CUSIPN/A
CIKN/A
Webwww.biopharmx.com
Phone+1-650-8895020

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees17
Outstanding Shares18,278,000
Market Cap$41.49 million
Next Earnings DateN/A
OptionableNot Optionable
AMEX:BPMX Rates by TradingView

Receive BPMX News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter.

Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Biopharmx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biopharmx.

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) posted its earnings results on Tuesday, December, 10th. The biotechnology company reported ($1.68) EPS for the quarter, topping analysts' consensus estimates of ($2.64) by $0.96. View Biopharmx's earnings history.

When did Biopharmx's stock split? How did Biopharmx's stock split work?

Biopharmx shares reverse split on Tuesday, May 19th 2020. The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for BPMX?

1 brokerages have issued 12 month price targets for Biopharmx's stock. Their forecasts range from $12.00 to $12.00. On average, they expect Biopharmx's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 428.6% from the stock's current price. View analysts' price targets for Biopharmx.

Has Biopharmx been receiving favorable news coverage?

Media stories about BPMX stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biopharmx earned a news sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Biopharmx.

Who are some of Biopharmx's key competitors?

What other stocks do shareholders of Biopharmx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), CytRx (CYTR), Protalix Biotherapeutics (PLX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN).

Who are Biopharmx's key executives?

Biopharmx's management team includes the following people:
  • Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
  • Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
  • Dr. José Zayas, Sr. VP of Operations
  • Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
  • Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs

What is Biopharmx's stock symbol?

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

How do I buy shares of Biopharmx?

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biopharmx's stock price today?

One share of BPMX stock can currently be purchased for approximately $2.27.

How big of a company is Biopharmx?

Biopharmx has a market capitalization of $41.49 million. Biopharmx employs 17 workers across the globe.

What is Biopharmx's official website?

The official website for Biopharmx is www.biopharmx.com.

How can I contact Biopharmx?

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.

This page was last updated on 7/14/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.